Egenesis
Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.
ICBiotec
Acquisition in 2020
ICBiotec, based in Mount Horeb, Wisconsin, specializes in advanced reproduction biotechnology services. The company focuses on providing cloning and related services to clients in academia and industry, both domestically and internationally. With a commitment to innovation in reproductive technologies, ICBiotec has developed state-of-the-art facilities supported by a highly skilled team of scientists and production personnel. The company's expertise lies in advancing reproduction for mammalian species, particularly within livestock.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.